UBS O'Connor’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-23,111
| Closed | -$3.15M | – | 365 |
|
|
2024
Q4 | $3.15M | Sell |
23,111
-8,559
| -27% | -$1.17M | 0.08% | 115 |
|
|
2024
Q3 | $3.65M | Buy |
31,670
+15,370
| +94% | +$1.77M | 0.09% | 118 |
|
|
2024
Q2 | $2.24M | Buy |
16,300
+2,300
| +16% | +$317K | 0.06% | 174 |
|
|
2024
Q1 | $1.93M | Sell |
14,000
-5,796
| -29% | -$799K | 0.06% | 177 |
|
|
2023
Q4 | $2.61M | Sell |
19,796
-14,002
| -41% | -$1.84M | 0.08% | 138 |
|
|
2023
Q3 | $3.8M | Sell |
33,798
-5,000
| -13% | -$563K | 0.07% | 158 |
|
|
2023
Q2 | $3.66M | Buy |
38,798
+7,616
| +24% | +$718K | 0.08% | 166 |
|
|
2023
Q1 | $3.16M | Buy |
+31,182
| New | +$3.16M | 0.07% | 197 |
|
|
2022
Q4 | – | Sell |
-17,003
| Closed | -$1.81M | – | 201 |
|
|
2022
Q3 | $1.81M | Sell |
17,003
-20,200
| -54% | -$2.15M | 0.02% | 648 |
|
|
2022
Q2 | $3.63M | Buy |
+37,203
| New | +$3.63M | 0.04% | 421 |
|
|
2016
Q3 | – | Sell |
-61,715
| Closed | -$2.81M | – | 430 |
|
|
2016
Q2 | $2.81M | Sell |
61,715
-51,829
| -46% | -$2.36M | 0.06% | 227 |
|
|
2016
Q1 | $4.49M | Buy |
+113,544
| New | +$4.49M | 0.08% | 214 |
|
|
2014
Q4 | – | Sell |
-100,000
| Closed | -$1.57M | – | 660 |
|
|
2014
Q3 | $1.57M | Buy |
100,000
+35,000
| +54% | +$548K | 0.03% | 305 |
|
|
2014
Q2 | $965K | Sell |
65,000
-31,671
| -33% | -$470K | 0.01% | 330 |
|
|
2014
Q1 | $1.56M | Buy |
+96,671
| New | +$1.56M | 0.03% | 301 |
|
|
2013
Q4 | – | Sell |
-73,900
| Closed | -$837K | – | 408 |
|
|
2013
Q3 | $837K | Buy |
+73,900
| New | +$837K | 0.02% | 304 |
|